Substance use disorders in adolescents with attention-deficit/hyperactivity disorder

Adolescent Medicine: State of the Art Reviews

Volumn 19, Issue 2, 2008, Pages 242-253

  Bukstein, Oscar ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT;

ADDICTION; ADOLESCENT; ATTENTION DEFICIT DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; GENETIC PREDISPOSITION; HUMAN; MASS SCREENING; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASS SCREENING; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 55949088235     PISSN: 19344287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Barkley R. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 3rd ed. New York, NY: Guilford Press; 2005
2. Substance Abuse Mental Health Services Administration. Results from the 2005 National Household Survey on Drug Use and Health: national findings. Available at www.oas.samhsa gov/nsduh/2k5nsduh/2k5Results.htm#TOC. Accessed July 15, 2007
3. Skounti M, Philalithis A, Galanakis E. Variations in prevalence of attention deficit hyperactivity disorder worldwide. Eur J Pediatr. 2007;166(2):117-123
4. Smalley SL, McGough JJ, Moilanen IK, et al. Prevalence and psychiatric comorbidity of attention-deficit/hyperactivity disorder in an adolescent Finnish population. J Am Acad Child Adolesc Psychiatry. 2007;46(12):1575-1583
5. US Department of Health and Human Services. 2003 National Survey on Drug Use and Health. SAMHSA, Office of Applied Studies. Available at www.oas.samhsa.gov/NSDUH/2k6NSDUH/2k6resuIts.cfm#Ch4. Accessed January 14, 2008
6. DeMilio L. Psychiatric syndromes in adolescent substance abusers. Am J Psychiatry. 1989; 146(9): 1212-1214
7. Gordon SM, Tulak F, Tróncale J. Prevalence and characteristics of adolescent patients with co-occurring ADHD and substance dependence. J Addict Dis. 2004;23(4):31-40
8. Halikas JA, Meiler J, Morse C, Lyttle MD. Predicting substance abuse in juvenile offenders: attention deficit disorder versus aggressivity. Child Psychiatry Hum Dev. 1990;21(1):49-55
9. Molina BSG, Bukstein OG, Lynch K. Attention-deficit/hyperactivity disorder and conduct disorder symptomatology in adolescents with alcohol use disorder. Psychol Addict Behav. 2002;16(2):161-164
10. Thompson LL, Riggs PD, Mikulich SK, Crowley TJ. Contribution of ADHD symptoms to substance problems and delinquency in conduct-disordered adolescents. J Abnorm Child Psychol. 1996;24(3):325-347
11. Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry. 2004;45(2): 195-211
12. Weiss M, Hechtman LT, Weiss G. ADHD in Adulthood. Baltimore, MD: Johns Hopkins University Press; 1999
13. Mannuzza S, Klein RG. Long-term prognosis in attention-deficit/ hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2000;9(3):711-726
14. Wilson JJ, Levin FR. Attention-deficit/hyperactivity disorder and early-onset substance use disorders. J Child Adolesc Psychopharmacol. 2005;15(5):751-763
15. Wilens T, Spencer T, Biederman J. Are attention-deficit/hyperactivity disorder and the psychoactive substance use disorders really related? Harv Rev Psychiatry. 1995;3(3):160-162
16. Biederman J, Monuteaux MC, Mick E, et al. Is cigarette smoking a gateway to alcohol and illicit drug disorders? A study of youths with and without attention deficit hyperactivity disorder. Biol Psychiatry. 2006;59(3):258-264
17. Flory K, Lynam DR. The relationship between attention deficit hyperactivity disorder and substance abuse: what role does conduct disorder play? Clin Child Fam Psychol Rev. 2003;6(1): 1-16
18. August GJ, Winters KC, Realmuto GM, Fahnhorst T, Botzet A, Lee S. Prospective study of adolescent drug use among community samples of ADHD and non-ADHD participants. J Am Acad Child Adolesc Psychiatry. 2006;45(7):824-832
19. Milberger S, Biederman J, Faraone S, Chen L, Jones J. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1997; 36(1):37-44
20. Burke JD, Loeber R, Lahey BB. Which aspects of ADHD are associated with tobacco use in early adolescence? J Child Psychol Psychiatry. 2001;42(4):493-502
21. Molina BSG, Pelham WE. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol. 2003;112(3):497-507
22. Kollins SH, McClemon J, Fuemmeler BF. Association between smoking and attention-deficit/ hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry. 2005;62(10):1142-1147
23. Elkins IJ, McGue, M, Iacono WG. Prospective effects of attention-deficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse. Arch Gen Psychiatry. 2007; 64(10): 1145-1152
24. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(11)1313-1323
25. Levin FR, Kleber HD. Attention-deficit/hyperactivity disorder and substance abuse: relationships and implications for treatment. Harv Rev Psychiatry. 1995;2(5):246-258
26. Wise RA. Brain reward circuitry: insights from unsensed incentives. In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, eds. Principles of Addiction Medicine. 3rd ed. Chevy Chase, MD: American Society of Addiction Medicine; 2003:57-71
27. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921
28. Kessler RC, Adler L, Ames M, et al. The World Health Organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005; 35(2):245-256
29. Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales. New York, NY: Multi-Health Systems; 1999
30. Brown TE. Brown Attention-Deficit Disorder Scales, Manual. San Antonio, TX: Harcourt Brace; 1996
31. Knight JR, Sherritt L, Shrier LA, Harris SK, Change G. Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Arch Pediatr Adolesc Med. 2002;156(6):607-614
32. Kollins SH. Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD). Am J Addict. 2007;16(suppl 1):35-44; quiz 43-44
33. Kollins SH, Rush CR, Pazzaglia PJ, Ali JA. Comparison of acute behavioral effects of sustainedrelease and immediate-release methylphenidate. Exp Clin Psychopharmacol. 1998;6(4):367-374
34. Spencer TJ, Biederman J, Ciccone PE. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry. 2006;163(3):387-395
35. Volkow ND, Ding Y, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry. 1995;52(6):456-463
36. Volkow N, Wang G, Fowler J, et al. Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addictions. Am J Psychiatry. 1999;156(1):19-26
37. Jasinski D, Krishnan S, Kehner G. Abuse liability of intravenous lisdexamfetamine (LDX; NRP 104). Presented at the 2006 annual meeting of the Society for Developmental and Behavioral Pediatrics; September 17, 2006; Philadelphia, PA
38. Boyd CJ, McCabe SE, Teter CJ. Medical and nonmedical use of prescription pain medication by youth in a Detroit-area public school district. Drug Alcohol Depend. 2006;81(1):37-45
39. Poulin C. Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. CMAJ. 2001;165(8):1039-1044
40. McCabe SE, Teter CJ. Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse. 2004;39(7):1095-1116
41. Wilens TW, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(1):21-31
42. Kroutil LA, Van Brunt DL, Herman-Stahl MA, Heller DC, Bray RM, Penne MA. Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend. 2006;84(2): 135-143
43. Williams RJ, Goodale LA, Shay-Fiddler MA, Gloster SP, Chang SY. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents. Am J Addict. 2004; 13(4):381-389
44. Hazell P. Pharmacological management of attention-deficit/hyperactivity disorder in adolescents. CNS Drugs. 2007;21(1):37-46
45. Riggs PD, Hall SK, Mikulich-Gilbertson SK, Lohman M, Kayser A. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents. J Am Acad Child Adolesc Psychiatry. 2004;43(4):420-429
46. Schubiner H, Saules KK, Arfken CL, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol. 2002;10(3):286-294
47. Levin FR, Evans SM, Brooks DJ, et al. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend. 2006;81(2):137-148
48. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2): 112-120
49. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 2002;67(2): 149-156
50. Davidson JT, Connor KM. Bupropion sustained release: a therapeutic overview. J Clin Psychiatry. 1998;59(suppl4):25-31
51. Griffith JD, Carranza J, Griffith C, Miller LI. Bupropion: clinical assay for amphetamine-like potential. J Clin Psychiatry. 1983;44(5 pt 2):206-208
52. Hurt RD, Sachs PPL, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337(17): 1195-1202
53. Dackis CA, Lynch KG, Yu E, et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend. 2003;70(1):29-37
54. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2004; 55(10): 1031-1040
55. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP. A double-blind, placebocontrolled trial of modafinil for cocaine dependence. Neuropsychopharmacology. 2005;30(1): 205-211
56. Rugino TA, Copley TC. Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study. J Am Acad Child Adolesc Psychiatry. 2001;40(2):230-235
57. Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics. 2005;116(6). Available at: www.pediatrics.org/cgi/content/full/116/6/e777